Treatment of Alzheimer's Disease subjects with expanded non-genetically modified autologous natural killer cells (SNK01): a phase I study

Table 7 Relationship of Biomarker level changes to changes in ADCOMS scores at week 11 compared to baseline

Cohort	Subject	AD Severity Stage	ADCOMS score CFB	Biomarkers CFB
Cohort	Subject	AD Severity Stage	ADCOMS score CFB	Aβ-42	Aβ-42/40	Tau (total)	Tau (pT181)	Tau (pT217)	α-Synuclein	GFAP	YKL-40	NfL
1	002	moderate	N	D	D	I	I	D	I	I	I	I
	003	moderate	N	I	I	I	D	I	D	I	D	I
	004	mild	N	I	I	I	I	I	I	I	I	I
	005	mild	D	D	D	D	D	D	D	D	D	D
2	006	severe	I	I	I	I	I	I	D	D	I	I
	007	mild	D	D	D	I	D	I	I	I	D	I
	011	mild	N	I	D	I	D	D	D	D	D	D
3	012	severe	N	I	I	D	D	D	D	D	D	I
	014	moderate	D	D	D	D	D	I	I	D	I	I
	015	mild	N	D	D	D	D	D	D	D	D	D
Percent of subjects with stable/ decrease in ADCOMS with positive^a biomarker changes				44.4	33.3	44.4	77.8	55.6	55.6	55.6	66.7	33.3

CFB Change from baseline, N no change from baseline, I Increase from baseline, D Decrease from baseline
^aA positive biomarker change is an increase for Aβ-42, Aβ42/Aβ40 ratio and a decrease for all other markers

ISSN: 1758-9193